Protagonist Therapeutics, Inc.PTGXNASDAQ
LOADING
|||
Switch Symbol:
EPS Growth Recovery in Progress
Trending higher, below historical average, slight contraction.
Left:
||||
Year-over-year earnings per share growth rate
Latest
-12.73%
↓ 221% below average
Average (39q)
10.50%
Historical baseline
Range
High:657.78%
Low:-189.47%
CAGR
-3.8%
Modest growth trend
| Period | Value |
|---|---|
| Q3 2025 | -12.73% |
| Q2 2025 | -189.47% |
| Q1 2025 | -109.00% |
| Q4 2024 | 490.74% |
| Q3 2024 | -8.00% |
| Q2 2024 | -114.66% |
| Q1 2024 | 657.78% |
| Q4 2023 | 177.59% |
| Q3 2023 | 14.71% |
| Q2 2023 | -9.68% |
| Q1 2023 | 3.13% |
| Q4 2022 | -3.23% |
| Q3 2022 | 25.30% |
| Q2 2022 | -93.02% |
| Q1 2022 | 44.16% |
| Q4 2021 | -10.00% |
| Q3 2021 | -1.45% |
| Q2 2021 | -27.78% |
| Q1 2021 | -12.50% |
| Q4 2020 | -128.57% |
| Q3 2020 | 64.41% |
| Q2 2020 | 18.06% |
| Q1 2020 | -14.29% |
| Q4 2019 | -3.28% |
| Q3 2019 | 48.31% |
| Q2 2019 | -103.45% |
| Q1 2019 | -1.75% |
| Q4 2018 | -50.00% |
| Q3 2018 | 7.32% |
| Q2 2018 | -13.89% |
| Q1 2018 | -140.00% |
| Q4 2017 | 48.28% |
| Q3 2017 | 67.42% |
| Q2 2017 | -5.95% |
| Q1 2017 | -25.37% |
| Q4 2016 | 20.24% |
| Q3 2016 | -95.35% |
| Q2 2016 | 78.50% |
| Q1 2016 | -115.05% |
| Q4 2015 | -57.63% |